Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Panel Favors Favipiravir, Tocilizumab As It Assesses COVID-19 Treatments

Strides Begins Favipiravir Exports, Glenmark to Start Trials

Executive Summary

In a preliminary assessment of repurposed COVID-19 treatments by a government-appointed panel to assess the readiness and potential of a drug to be used in India, favipiravir and tocilizumab have emerged as front-runners. With Strides Pharma exporting the antiviral and Glenmark set to begin clinical trials, even the industry is supporting favipiravir, which is already in studies in Japan and China.

You may also be interested in...



Strides Optimistic On Prospects Of Antiviral Portfolio For COVID-19

Optimistic about the potential of repurposing its antiviral portfolio, Strides plans to soon begin bioequivalence studies for favipiravir, a molecule that has found favor as a COVID-19 therapy in a few countries. It also aims to introduce new products to fill the gap left by the withdrawal of ranitidine from the US market.

Gilead's Remdesivir Results Encouraging, Safety Brings Skepticism

Analysts see NIAID’s placebo-controlled data as more important than Gilead’s open-label data. Quick emergency use authorization by FDA is possible, but the US agency has not confirmed EUA.

Coronavirus Update: Moderna Prepares For Crucial Phase II Trial Of Vaccine, Japan Takes Steps

Plus: Japan pledges rapid approval for remdesivir, GSK launches fund to look into impact of coronavirus on people with HIV.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142222

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel